OABI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

OmniAb Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.98 USD
-2.5% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 1.5% above the Trend Line and sits at 45.6% of its 52-week range. The latest completed week returned -2.5%, after a -18.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 32 out of 100
Latest Close 1.98 USD 31 Jul 2026
1W Return -2.5% latest completed week
4W Return -18.2% short-term follow-through
12W Return 19.3% quarterly tape
Trend Breadth 34.6% 18 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • The trend backdrop is active with a 10-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 36.37% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.5% Latest completed week; four-week move -18.2%. Indicator stack 54/44 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 36.37% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 37.1%. News sentiment 54/100 57 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 1.5% above the Trend Line and sits at 45.6% of its 52-week range. The latest completed week returned -2.5%, after a -18.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7712-week average 0.46

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.77Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -18.2% over four weeks, 19.3% over 12 weeks, and 3.7% over one year. The current trend has remained active for 10 consecutive weeks.

Performance by holding period

1W-2.5%
4W-18.2%
12W19.3%
26W8.8%
52W3.7%
Active trend streak10 weeks
Active weeks in one year18
Trend breadth34.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.06Latest activity-pressure read.
Pressure change-91.6%Four-week change in activity pressure.
Leadership-2.36Latest relative-leadership reading.
RS change-117.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength7/100Blend of value, momentum, and quality. Underlying universe rank 94; rank 1 is best.
Value26/100Relative valuation strength. Underlying universe rank 75; rank 1 is best.
Quality5/100Profitability and accounting quality. Underlying universe rank 96; rank 1 is best.
Momentum30/100Medium-term price momentum. Underlying universe rank 71; rank 1 is best.
Growth67/100Revenue and earnings growth. Underlying universe rank 34; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
10.2x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-8.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
35.5%
Gross profit retained from each unit of revenue.
Operating margin
-196.6%
Operating profit retained from revenue.
Free-cash-flow margin
-86.4%
Free cash flow generated from revenue.
Return on invested capital
-16.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-9.6%
Net share repurchases relative to market value.
Shareholder yield
-9.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

OABI shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 37.1%, and Sharemaestro trend signal active.

Conviction52/100
Expected move37.1%
Put/call volume0.00
Pressure100
Speculation1
Volatility96
Trend agreement2
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 57 relevant articles.

16 positive · 36 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move37.1%Nearest-chain priced movement where available.
52-week drawdown-29.0%Distance below the 52-week high.
13-week volatility12.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2614 weeks finished lower.
Best week+31.3%Week of 15 May.
Worst week-13.7%Week of 27 Mar.
Latest week-2.5%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains4
Flat weeks2
Modest losses3
Sharp losses11
Recent vol12.3%13-week weekly-return volatility.
Base vol8.7%52-week weekly-return volatility.
Up/down split22/27Count of positive and negative weeks in the 52-week window.
Average skew8.0% / -5.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape35/100

Trend, activity pressure, participation, and risk combine to a 35/100 tape read.

 Indicator analysis80/100

Latest 12-week confirmation: trend 10/12, activity pressure 11/12, relative leadership 11/12.

Activity pressure 0.77; No reversal markers Next-Week ExpectancyNegative 36.37%

Next-week expectancy is negative with a 36.37% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors15/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 86; Small Cap Core rank 76 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

OABI shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 37.1%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 37.1% Sentiment54/100

Weighted news tone is neutral across 57 relevant articles.

Number of shareholders of OmniAb, Inc. – NASDAQ:OABI Insiders50/100

No recent insider transaction evidence is stored.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.98 USD-2.5%1.95 USD3.33 USD0.06-2.361.4MOn
24 Jul 20262.03 USD-4.2%1.95 USD3.35 USD0.310.271.9MOn
17 Jul 20262.12 USD-7.4%1.94 USD3.37 USD0.612.542.2MOn
10 Jul 20262.29 USD-5.4%1.94 USD3.39 USD0.765.863.7MOn
3 Jul 20262.42 USD-4.0%1.94 USD3.41 USD0.7613.511.7MOn
26 Jun 20262.52 USD7.7%1.92 USD3.42 USD0.8519.154.3MOn
19 Jun 20262.34 USD3.1%1.90 USD3.44 USD0.875.972.7MOn
12 Jun 20262.27 USD-8.5%1.88 USD3.46 USD1.045.641.9MOn
5 Jun 20262.48 USD-8.1%1.86 USD3.47 USD1.1917.892.8MOn
29 May 20262.70 USD1.9%1.82 USD3.49 USD1.0223.112.7MOn
22 May 20262.65 USD21.6%1.78 USD3.50 USD0.4625.305.1MOff
15 May 20262.18 USD31.3%1.75 USD3.51 USD-0.055.005.0MOff
8 May 20261.66 USD18.6%1.73 USD3.52 USD-0.39-20.297.3MOff
1 May 20261.40 USD-4.1%1.73 USD3.53 USD-0.72-29.372.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.